Tagged with IP

Saudi Arabia This interview explores Bayer’s strategic initiatives across the Middle East and North Africa (MENA) region, highlighting its commitment to innovation, local talent development, and sustainability. Over the next few years, Bayer aims to enhance accessibility to groundbreaking healthcare solutions while deepening relationships with local and international stakeholders. As Hugo Hagen,…

China EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and unique molecule formats, EpimAb has differentiated itself with safer, more effective therapies than its competitors, as well as how the…

Puerto Rico Ella Woger-Nieves of Invest Puerto Rico highlights the island’s remarkable evolution into a global pharmaceutical manufacturing, life sciences, and innovation hub. Woger-Nieves explains how, over the past five years, Puerto Rico has expanded its capabilities in research and development, fostered collaboration between startups and legacy companies, and positioned itself as…

UAE Baptiste de Clarens lays out how Sanofi is leveraging its innovative vaccine pipeline, including high-dose flu vaccines and RSV monoclonal antibodies, to drive growth in the GCC region. Despite challenges like vaccine scepticism in adult immunisation, the company is focused on strengthening vaccination infrastructure and public health awareness. de Clarens…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

Global Dr Catherine Duggan, CEO of the International Pharmaceutical Federation, lays out how mental health systems must shift from reactive crisis intervention to proactive, patient-centered approaches; why traditional care models need reimagined funding that prioritises community mental health services and incentivises innovation; and the vital role that pharmacists, as accessible healthcare…

Switzerland Adrian Hunn of Swiss Medtech, shares insights into his role and the future of Switzerland’s medtech sector. He discusses the association’s focus on fostering innovation, navigating regulatory challenges, and promoting international collaboration to position Switzerland as a global leader. Hunn highlights key initiatives, such as supporting digital healthcare, sustainability efforts,…

Global Pfizer CEO Albert Bourla’s ‘annus horribilis’ shows no sign of abating. From being feted as the industry darling of the COVID-19 period, Pfizer management is now being accused of USD 20 billion worth of “value destruction” by activist investors. As new analysis shows, Bourla has also suffered the ignominy of…

Switzerland Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European counterparts when it comes to healthcare digitalisation. Recent PharmaBoardroom interviewees weigh in on the country’s digital lag, its electronic patient…

Global The Top 10 medical device manufacturers for 2024 ranked by sales value for the past year. As compiled by Medical Product Outsourcing, Medtronic sits at the top of this year’s list with a full USD 32.36 billion in sales, driven primarily by organic rather than acquisition-based growth. J&J Medtech is…

France At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi, Ipsen, and Pierre Fabre – arguments were made for increasing efficiency in a healthcare system that is “on its last…

Switzerland Ernst Niemack, managing director of vips, the association representing pharmaceutical companies operating in Switzerland, comments on the government’s latest cost containment measures such as mandatory rebates and new rules for biosimilars and generics, and the impact of these policies on innovative pharma. He also discusses the lag between registrations and…